New flu vaccine for toddlers shows promise in large trial

NCT ID NCT05645900

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large Phase 3 trial tested a new quadrivalent flu vaccine in over 2,700 healthy children aged 6 to 35 months. The study compared two doses of the experimental vaccine against a standard flu vaccine to see how well it triggers an immune response and whether it is safe. Researchers monitored side effects and collected blood samples to measure antibody levels. The trial is now complete, and results will show if this vaccine is a good option for protecting young children from the flu.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
quadrivalent influenza virus subunit vaccine
What this could lead to
If successful, this could provide a safe and effective flu vaccine option for young children, helping to reduce flu illness in this age group.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The vaccine may not prove more effective than existing options, and side effects like fever or injection site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ab&b Biotechnology Co., Ltd.JS

    Taizhou, Jiangsu, 225300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.